KatieB Posted November 20, 2017 Share Posted November 20, 2017 Phase III IMPOWER 150 study showed that Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy significantly reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced lung cancer. These data are not fully mature and the next OS analysis is expected in the first half of 2018. They will be submitting these results to health authorities globally (FDA and EMA). You can read more about the study here https://www.gene.com/media/press-releases/14692/2017-11-19/phase-iii-impower150-study-showed-genent Steff 1 Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.